- Obama says Boosting US Jobs is Top Priority
- More Consumers Giving 'Black Friday' the Cold Shoulder
- Prepare For Large Decline In Stocks, Next Year?
- Hewlett-Packard Earnings Rise, Match Guidance
- HP Comes in As Expected; Is It Time to Buy?
- Cramer: What Monday’s Housing Number Really Means
- Why the Dollar Will Likely Stay Weak for Some Time
- Bear, Lehman Execs Weren't Wiped Out by Crisis: Study
- How Real Estate Investors Skew Housing's Reality
- Can Murdoch Help Bing Challenge Google and Shift the Content Equation?
- HP's Mark Hurd
- HP Comes in As Expected; Is It Time to Buy?
- 9 Stocks That Play Rising Water Costs: Strategists
- Weis' Deal Likely Won't Change Big Money Contracts
- Gold Prices Can Double in 3 Years: Portfolio Manager
- Nov. 23: Unusual Volume Leaders
- Help Wanted—Please Run $4 Billion University
- Apple Comes to AT&T's Rescue
- Clothing sales down Nov., but online roars back
- SKorea pledges to double aid to Africa
- Govt issues record 2.1M recall for dropside cribs
- China planning agency OKs Shanghai Disney project
- China Eastern Airlines teams up with Alibaba
- Kinder Morgan expects to pay $4.40 annual dividend
- Mich. spammer gets 4 years in stock fraud scheme
- Icahn outbids Penn to open Fontainebleau auction
- Max Capital names new president of reinsurance ops
Text Size 
NEW YORK - Bristol-Myers Squibb Co. shares will offer greater risks and rewards after the company completes its split from Mead Johnson Nutrition Co., a Credit Suisse analyst said Monday.
The splitoff "removes Bristol-Myers Squibb's last source of earnings diversification," said analyst Catherine Arnold. The move is intended to help Bristol-Myers focus on buying and developing biotech drugs. Arnold said she expects the company's shares to trade lower on Monday.
On Sunday, Bristol-Myers said it will split off its 83 percent stake in Mead Johnson, the maker of children's nutritional products like Enfamil baby formula. Bristol-Myers shareholders will be able to swap their shares in exchange for a discount price on Mead Johnson shares.
Arnold believes the deal will boost the New York drugmaker's profit by cents per share in 2010.
Another Credit Suisse analyst, Robert Moskow, said Mead Johnson shares could fall 10 to 15 percent Monday because of the discount price, and because the split suggests Bristol-Myers was unable to sell Mead Johnson for as much as it wanted. He put that price at $60 per share.
In premarket trading, Bristol-Myers Squibb shares rose 2.7 percent, or 63 cents, to $23.80 from Friday's closing price of $23.18.
Print
Email
- The show attracts a big TV audience every year, but this year it may take on even more importance.
- …you'll want to be prepared. Tips for getting the most out of the post-Thanksgiving shopping frenzy.
- Congressman Ron Paul explains to Squawk Box why he’s pushing legislation to audit the Federal Reserve.
- CNBC’s Phil LeBeau took a test drive of GM’s flagship electric car. Here’s what he thought of the Volt.
- The energy company Power Efficiency is building tools that regulate the power electric motors use.
- CNBC’s technology reporter Jim Goldman guides you through the best gadgets to buy this holiday season.
Data is a real-time snapshot *Data is delayed at least 15 minutes